Pancreatic Cancer Research

ResearcherUniversity of UtahNo recent work listed

Shane A. J. Lloyd

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4235-7652; OpenAlex author ID A5057200744. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 1, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 4 papers · 2019: 2 papers, 1 trial · 2020: 1 paper

Papers 10

  1. The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Last author DOI 10.1002/cam4.2851↗
  2. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative … Co-author DOI 10.1007/s11605-018-3953-0↗
  3. Correlates of Refusal of Surgery in the Treatment of Non-metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-018-6708-y↗
  4. Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. Last author DOI 10.1136/esmoopen-2017-000282↗
  5. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.21037/jgo.2018.04.03↗
  6. Large database utilization in health outcomes research in pancreatic cancer: an update. Last author DOI 10.21037/jgo.2018.05.15↗
  7. Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. Last author DOI 10.21037/jgo.2018.05.16↗
  8. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. First author DOI 10.1002/cncr.30780↗
  9. A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2013.011↗
  10. New possibilities and potential benefits for local control in locally recurrent pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2013.049↗

Trials 1

  1. Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer Principal investigator NCT04106856↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ignacio Garrido‐Laguna · 6 shared papers, 2017–2020 · strength 0.60
  2. Anna M. Torgeson · 5 shared papers, 2017–2019 · strength 0.54
  3. Bryan William Chang · 3 shared papers, 2013–2018 · strength 0.24
  4. Joshua David Gruhl · 2 shared papers, 2019–2020 · strength 0.23
  5. Courtney L. Scaife · 2 shared papers, 2018–2019 · strength 0.19
  6. George M. Cannon · 2 shared papers, 2017–2018 · strength 0.17
  7. Alex Coffman · 1 shared paper, 2019 · strength 0.16
  8. Kajsa E. Affolter · 1 shared paper, 2020 · strength 0.13
  9. Snehal Gajiwala · 1 shared paper, 2018 · strength 0.11
  10. Conan Kinsey · 1 shared paper, 2018 · strength 0.11
  11. Douglas S. Swords · 1 shared paper, 2019 · strength 0.09
  12. Matthew A. Firpo · 1 shared paper, 2019 · strength 0.09
  13. Sean J. Mulvihill · 1 shared paper, 2019 · strength 0.09
  14. Stacey Stein · 1 shared paper, 2018 · strength 0.09
  15. Charles E. Rutter · 1 shared paper, 2018 · strength 0.09
  16. Brandon R. Mancini · 1 shared paper, 2018 · strength 0.09
  17. Jill Lacy · 1 shared paper, 2018 · strength 0.09
  18. Kimberly L. Johung · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.